Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds

被引:58
作者
Udy, Andrew A. [1 ,2 ]
Jarrett, Paul [3 ]
Stuart, Janine [3 ]
Lassig-Smith, Melissa [3 ]
Starr, Therese [3 ]
Dunlop, Rachel [3 ]
Wallis, Steven C. [2 ]
Roberts, Jason A. [2 ,3 ]
Lipman, Jeffrey [2 ,3 ]
机构
[1] Alfred, Dept Intens Care & Hyperbar Med, Melbourne, Vic 3181, Australia
[2] Univ Queensland, Burns Trauma & Crit Care Res Ctr, Brisbane, Qld 4029, Australia
[3] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Brisbane, Qld 4029, Australia
来源
CRITICAL CARE | 2014年 / 18卷 / 06期
基金
英国医学研究理事会;
关键词
GLOMERULAR-FILTRATION-RATE; PLASMA CREATININE CONCENTRATIONS; INTENSIVE-CARE-UNIT; PARA-AMINOHIPPURATE; ELIMINATION PATHWAYS; SINISTRIN CLEARANCE; FLUCONAZOLE; PINDOLOL; KIDNEY; PHARMACOKINETICS;
D O I
10.1186/s13054-014-0657-z
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Introduction: The aim of this study was to explore changes in glomerular filtration (GFR) and renal tubular function in critically ill patients at risk of augmented renal clearance (ARC), using exogenous marker compounds. Methods: This prospective, observational pharmacokinetic (PK) study was performed in a university-affiliated, tertiary-level, adult intensive care unit (ICU). Patients aged less than or equal to 60 years, manifesting a systemic inflammatory response, with an expected ICU length of stay more than 24 hours, no evidence of acute renal impairment (plasma creatinine concentration <120 mu mol/L) and no history of chronic kidney disease or renal replacement therapy were eligible for inclusion. The following study markers were administered concurrently: sinistrin 2,500 mg (Inutest; Laevosan, Linz, Austria), p-aminohippuric acid (PAH) 440 mg (4% p-aminohippuric acid sodium salt; CFM Oskar Tropitzsch, Marktredwitz, Germany), rac-pindolol 5 or 15 mg (Barbloc; Alphapharm, Millers Point, NSW, Australia) and fluconazole 100 mg (Diflucan; Pfizer Australia Pty Ltd, West Ryde, NSW, Australia). Plasma concentrations were then measured at 5, 10, 15, 30, 60 and 120 minutes and 4, 6, 12 and 24 hours post-administration. Non-compartmental PK analysis was used to quantify GFR, tubular secretion and tubular reabsorption. Results: Twenty patients were included in the study. Marker administration was well tolerated, with no adverse events reported. Sinistrin clearance as a marker of GFR was significantly elevated (mean, 180 (95% confidence interval (CI), 141 to 219) ml/min) and correlated well with creatinine clearance (r = 0.70, P < 0.01). Net tubular secretion of PAH, a marker of tubular anion secretion, was also elevated (mean, 428 (95% CI, 306 to 550) ml/min), as was net tubular reabsorption of fluconazole (mean, 135 (95% CI, 100 to 169) ml/min). Net tubular secretion of (S) -and (R)-pinodolol, a marker of tubular cation secretion, was impaired. Conclusions: In critically ill patients at risk of ARC, significant alterations in glomerular filtration, renal tubular secretion and tubular reabsorption are apparent. This has implications for accurate dosing of renally eliminated drugs.
引用
收藏
页数:9
相关论文
共 47 条
[1]   Pharmacokinetic-Pharmacodynamic Considerations in the Design of Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia Studies: Look before You Leap! [J].
Ambrose, Paul G. ;
Bhavnani, Sujata M. ;
Ellis-Grosse, Evelyn J. ;
Drusano, George L. .
CLINICAL INFECTIOUS DISEASES, 2010, 51 :S103-S110
[2]   Augmented renal clearance in septic patients and implications for vancomycin optimisation [J].
Baptista, Joao Pedro ;
Sousa, Eduardo ;
Martins, Paulo J. ;
Pimentel, Jorge M. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2012, 39 (05) :420-423
[3]   Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group [J].
Bellomo, R ;
Ronco, C ;
Kellum, JA ;
Mehta, RL ;
Palevsky, P .
CRITICAL CARE, 2004, 8 (04) :R204-R212
[4]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[5]   Assessing glomerular filtration rate (GFR) in critically ill patients with acute kidney injury true GFR versus urinary creatinine clearance and estimating equations [J].
Bragadottir, Gudrun ;
Redfors, Bengt ;
Ricksten, Sven-Erik .
CRITICAL CARE, 2013, 17 (03)
[6]   RENAL-FUNCTION IN CRITICALLY ILL POSTOPERATIVE-PATIENTS - SEQUENTIAL ASSESSMENT OF CREATININE OSMOLAR AND FREE-WATER CLEARANCE [J].
BROWN, R ;
BABCOCK, R ;
TALBERT, J ;
GRUENBERG, J ;
CZURAK, C ;
CAMPBELL, M .
CRITICAL CARE MEDICINE, 1980, 8 (02) :68-72
[7]   Sinistrin clearance for determination of glomerular filtration rate: A reappraisal of various approaches using a new analytical method [J].
Buclin, T ;
PechereBertschi, A ;
Sechaud, R ;
Decosterd, LA ;
Munafo, A ;
Burnier, M ;
Biollaz, J .
JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (08) :679-692
[8]   Estimation of glomerular filtration rate by sinistrin clearance using various approaches [J].
Buclin, T ;
Sechaud, R ;
Bertschi, AP ;
Decosterd, LA ;
Belaz, N ;
Appenzeller, M ;
Burnier, M ;
Biollaz, J .
RENAL FAILURE, 1998, 20 (02) :267-276
[9]   Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function [J].
Buijk, SLCE ;
Gyssens, IC ;
Mouton, JW ;
Verbrugh, HA ;
Touw, DJ ;
Bruining, HA .
INTENSIVE CARE MEDICINE, 2001, 27 (01) :115-121
[10]   Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? [J].
Carlier, Mieke ;
Carrette, Sofie ;
Roberts, Jason A. ;
Stove, Veronique ;
Verstraete, Alain ;
Hoste, Eric ;
Depuydt, Pieter ;
Decruyenaere, Johan ;
Lipman, Jeffrey ;
Wallis, Steven C. ;
De Waele, Jan J. .
CRITICAL CARE, 2013, 17 (03)